2021 Online, In the cloud

I-01 Ana Alarcia
Population pharmacokinetic modelling of levetiracetm in criticaclly ill patients. Influence of creatinine clearance on the probability to attain target concentrations.
I-02 Michael Cloesmeijer
Capped dosing of desmopressin in Von Willebrand disease: Quantification of the relationship between desmopressin plasma concentration and Von Willebrand factor activity
I-03 Alix Demaris
Simulation based assessment of different dosing strategies for anti-TNFα monoclonal antibodies in Crohn’s disease patients
I-04 Thomas Dumortier
A model-based approach to support a label update for flexible dosing of secukinumab in patients with plaque psoriasis
I-05 Omar Elkayal
Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and exposure in term neonates
I-06 Ruben Faelens
Building model-informed precision dosing software using R: blueprint for a state-of-the-art development process
I-07 Wannee kantasiripitak
A multi-model averaging approach improves the performance of model-guided infliximab de-escalation in patients with inflammatory bowel diseases
I-08 Simon Koele
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients
I-09 Matthias König
A physiologically based computational model of indocyanine green liver function tests predicts survival in hepatectomy
I-10 Enrica Mezzalana
Population pharmacokinetic modelling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment
I-11 Robin Michelet
Using microdose-based activity measurement to individualise dosing of cytochrome P450 metabolised drugs: a case study with yohimbine and tamoxifen
I-12 Sami Ullah
Population pharmacokinetics suggests that an intraperitoneal daily dose of 750 mg meropenem is sufficient to treat peritonitis in patients undergoing automated peritoneal dialysis
I-14 Niklas Hartung
Nonparametric goodness-of-fit testing for parametric covariate models
I-15 Sara Carolina Henriques
Population pharmacokinetic analysis on data from a bioequivalence study – Effects of hormonal contraceptives on drug exposure
I-16 Galina Kolesova
Virtual Patient Populations: Comparison of Approaches in Application to QSP Model Of Erythropoiesis
I-17 Venelin Mitov
A unifying approach to sampling NLME model parameters
I-18 Giovanni Smania
Conditional distribution modeling for covariates simulation using classification and regression trees methods
I-19 Asuka Suzuki
Applying parametric bootstrap to generating a distribution of pseudo-objective function value difference for model selection in population pharmacokinetic analysis under time zone-specific nonexistence of observations
I-20 Veronika Voronova
Exposure-safety analysis for oral GLP-1 analogues: the impact of between-occasion variability in drug absorption on nausea probability
I-21 Geraldine Ayral
Simulation of first-in-human using an allometrically scaled population mechanistic TMDD model with preclinical monkey data, using the MonolixSuite
I-22 Emmanuelle Comets
Additional features and graphs in the new npde library for R
I-23 Alexandre Duong
External evaluation of population pharmacokinetic models of gentamicin in critically ill patients
I-24 Mehdi El Hassani
Impact of sampling times on the predictive performance of tobramycin population pharmacokinetic models
I-25 Ibrahim El-Haffaf
Simulation of the impact of unbound fraction variations on the predictive performance of a piperacillin-tazobactam population pharmacokinetic model.
I-26 Hanna Kunina
Model Averaging Applied to Models With Various Biomarkers Using Multiple Weighting Methods
I-28 Fatemeh Aghai
Physiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction
I-29 Laura Bem Olivo
Pharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy
I-30 Pavlos Chrysafidis
A paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models.
I-31 Rebekka Fendt
Systematic evaluation of personalized physiologically based pharmacokinetic simulations
I-32 Angele Fleury
A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine
I-33 Bart Lammens
A Physiologically Based Pharmacokinetic (PBPK) Model of Sildenafil to Predict Exposure in Pregnant Females. What is missing?
I-34 Jennifer Lang
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions
I-35 Antonina Nikitich
Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors
I-36 Luna Prieto Garcia
Simvastatin disposition described by physiologically based pharmacokinetics: Does choice of applied PBPK platform matter?
I-37 Javier Reig-López
Physiologically Based Pharmacokinetic Model for Atorvastatin: New Insights in Enzymatic and Transport Processes.
I-38 Mohammed Saleh
Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach
I-39 Ayatallah Saleh
Physiologically-based pharmacokinetic (PBPK) modelling to explore the pharmacokinetics (PK) and drug-drug interactions (DDI) potential of midazolam and 1-hydroxymidazolam: the hypothesis of lysosomal trapping
I-40 Christina Schräpel
Physiologically based pharmacokinetic (PBPK) modeling of (E)-clomiphene drug-drug-gene interactions with CYP2D6 and clarithromycin
I-41 Jennifer Tardiveau
A Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline
I-42 Sung-yoon Yang
Application of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine.
I-43 Emma Eckernäs
Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine
I-44 Berfin Gülave
Opioids distribution in human CNS might be altered due to pain-related increase of BBB permeability.
I-45 Hee Yoon Jung
Equivalent dose prediction of donepezil patch using population pharmacokinetic oral and patch combination model
I-46 Tatiana Karelina
Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease
I-47 Orestis Papasouliotis
Phase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis
I-48 Satoshi Shoji
Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies
I-49 Satoshi Shoji
Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model
I-50 Hanna Silber Baumann
Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers.
I-51 Jae Eun Ahn
Model-Based Meta-Analysis of Triglyceride Reduction in Patients with Hypertriglyceridemia
I-52 Alessandro Boianelli
Understanding the relationship between in vitro potency, nausea and clinical efficacious concentrations for GLP-1 receptor agonists
I-54 Kwan Cheol Pak
PK and PD modeling and simulation of GX-H9 in the adult patients with growth hormone deficiency
I-55 Daniel Röshammar
The population PKPD of unacylated and acylated ghrelin following single rising doses of BI 1356225 in healthy subjects is impacted by the time since last meal
I-56 Elrod Chris
SAEM in Pumas – A systematic evaluation and benchmarking
I-57 Charles Margossian
Solving ODEs in a Bayesian context: challenges and opportunities
I-58 Andreas Noack
Generalized FOCE with Pumas
I-59 Monika Twarogowska
Implementation of the standard concentration - QTc study using MonolixSuite applications on the example of Dofetilide.
I-60 Sergei Vavilov
Parameter estimation in nonlinear fixed-effects QSP models: benchmark of optimization methods
I-61 Yi Zhang
Torsten: Stan functions for pharmacometric applications - Improvements and new R interface workflow
I-62 Silvia Grandoni
Therapeutic effect of anti-IL6 monoclonal antibodies in the treatment of COVID-19 in adults and multisystem inflammatory syndrome in children using siltuximab as a case study
I-63 Charlotte Kern
Modeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect
I-64 Timothy Knab
A Physiologically-based Pharmacokinetic Modeling Approach to Support Candidate and First in Human Dose Selection for Bamlanivimab
I-65 Tarunendu Mapder
Antiviral Treatment on SARS-Cov-2 Infected Epithelial Tissue Patch
I-66 Aurélien MARC
Developing a model of SARS-CoV-2 viral dynamics under monoclonal antibody treatment.
I-67 Dirk Jan Moes
Towards fixed dosing of tocilizumab in ICU admitted COVID-19 patients; results of an observational population pharmacokinetic and descriptive pharmacodynamic study
I-68 Venkatesh Pilla Reddy
Application of modelling and simulation in development of an antibody cocktail for the prevention and treatment of COVID-19
I-69 Jingxian Chen
Pharmacokinetics Optimization of Phase 2b/3 Study in Infants to Support the Development an RSV Monoclonal Antibody (MK-1654)
I-70 Romain Leroux
New features in PFIM for optimal design in nonlinear mixed effects models using the S4 object system in R
I-71 Claude Magnard
Simulx-GUI: a flexible, fast and user-friendly application for simulations
I-72 Yuanxi Zou
A novel approach to evaluate the design of pediatric PK studies focused on accurate dose selection
I-73 Jiyeong Byeon
Population PK-PD modeling and simulation of zolpidem to evaluate dosage regimen for sex effect in healthy Korean volunteers
I-74 Alejandra Schiavo
A QSP model characterizing valproic acid -induced hyperammonemia and the impact of carnitine supplementation
I-75 Roberta Bartolucci
Development of a genetic algorithm for covariate analysis in population pharmacokinetic models
I-76 Iasonas Kapralos
Population pharmacokinetic modeling of the complex release kinetics of octreotide LAR: Defining sub-populations by cluster analysis
I-78 Ivan Borisov
HetaProject – a Single Open Source Platform for Modeling, Simulation and Parameters Estimation in QSP
I-79 Jason Chittenden
TADAH, a Shiny Application for Producing Report Ready Anti-Drug Antibody (ADA) Tables for MS Word
I-80 Ekaterina Mogilevskaya
CYTOCON DB as storage of unified data on in vivo human concentrations of cells and molecules in health and disease
I-81 Rikard Nordgren
Open source software from the Uppsala University Pharmacometrics group
I-82 Tarjinder Sahota
NMproject new interface: end-to-end script-based NONMEM model development in RStudio